Foghorn Therapeutics Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The company is a clinical-stage biotechnology business developing medicines that target the chromatin regulatory system; it has no approved products and has generated no product-sale revenue.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Collaboration revenue | $0.43 million | None |
| Research and development expense | $57.7 million | $44.4 million |
| General and administrative expense | $11.2 million | $6.7 million |
| Net loss | $68.8 million | $51.1 million |
| Net loss per share, basic and diluted | $6.23 | $12.20 |
| Cash used in operating activities | $31.3 million | $46.3 million |
- At year-end, cash and cash equivalents were $92.8 million and marketable securities were $93.0 million, totaling $185.8 million. Current assets were $190.7 million versus current liabilities of $18.8 million.
- Total assets were $255.6 million; total liabilities were $109.4 million. Notes payable were $20.0 million gross ($19.7 million net of discount), with an 8.0% interest rate at year-end. Principal repayments begin in December 2023, with final maturity in November 2025; a 5% final payment fee applies.
- Operating lease liabilities totaled $62.3 million. The filing does not provide a meaningful product gross margin: revenue was collaboration-based, not product sales.
- Accumulated deficit was $162.9 million. No income tax benefit was recorded, and a full valuation allowance covered net deferred tax assets.
Changes and financing
- Net loss increased by $17.7 million year over year as operating expenses rose $17.9 million, including higher R&D, staffing, facility and public-company costs. R&D increased $13.4 million; G&A increased $4.5 million.
- Operating cash use declined year over year, partly reflecting working-capital movements, including the Merck upfront payment recorded as deferred revenue and landlord incentives. Investing activities used $108.9 million, mainly for $93.0 million of marketable-security purchases and $16.2 million of property and equipment.
- Financing provided $217.5 million, principally from the October 2020 IPO (approximately $122.1 million net) and Series B preferred stock proceeds ($89.9 million net). Preferred stock converted to common stock upon the IPO.
Business outlook, milestones and risks
- FHD-286: The company was initiating parallel Phase 1 studies for metastatic uveal melanoma and relapsed/refractory AML after FDA acceptance of the INDs in late December 2020 and early January 2021. Management expected preliminary clinical proof-of-concept data as early as Q4 2021. These early trials primarily assess safety and tolerability; efficacy is not established.
- FHD-609: Preclinical development for synovial sarcoma; management planned to submit an IND in Q2 2021 and, if cleared, start a Phase 1 study shortly afterward. GLP toxicology studies were completed.
- Management planned to begin IND-enabling studies for a selective BRM modulator in the second half of 2021 and continue ARID1B preclinical work. These are forward-looking plans, not achieved milestones.
- Cash, cash equivalents and marketable securities were expected to fund operating expenses, capital expenditures and debt service into Q3 2022, based on assumptions management cautioned may prove inaccurate. The financial-statement note separately states resources were expected to cover at least 12 months from issuance. Additional funding will be needed; future financing may be unavailable or dilutive.
- The Merck collaboration provided a $15.0 million upfront payment, of which $0.4 million was recognized as 2020 revenue and $14.6 million remained deferred. Foghorn may receive up to $245 million in research, development and regulatory milestones, up to $165 million in sales milestones per approved product, and tiered royalties; future payments are uncertain. Merck may terminate for convenience.
- Key risks include clinical and regulatory failure, unproven mechanisms, competition, dependence on third-party manufacturers and research organizations, COVID-19-related disruption, and limited patent protection. As of the filing’s stated date, the company had no issued patents covering FHD-286, FHD-609 or its platform; platform protection relies substantially on trade secrets and know-how.
Investor verification priorities
- Check subsequent filings for actual FHD-286 trial initiation, enrollment, safety findings and timing of any data; confirm the planned FHD-609 IND and trial milestones.
- Track cash and marketable securities, operating cash burn, financing needs and the assumptions behind management’s runway estimate.
- Review debt terms, including interest, collateral, covenants, repayment schedule and the final payment fee; assess lease commitments alongside financing capacity.
- Monitor Merck collaboration research progress, revenue recognition, any milestone eligibility and potential termination or scope changes.
- Verify patent prosecution progress and the strength of protection for the lead candidates and platform, as well as any material COVID-19, manufacturing or clinical-trial disruptions.